Clinical Characteristics of the Study Sample.

<p>Results as mean ± SD; ns: no significant different when p>0.05.</p><p>(PPAD, premature peripheral arterial diseases; PAOD, peripheral arterial occlusive disease; TAO, thromboangiitis obliterans).</p

PCR analysis of genomic DNA encoding the glycoprotein Ia gene surrounding the 807, 837 and 873 polymorphisms.

<p><i>(A)</i> Amplified products (1332 bp) were resolved by 1% agarose gel electrophoresis and stained with ethidium bromide. Lane 1: molecular weight marker; lane 2: blank; lanes 3 to 11: different genotyped individuals. <i>(B)</i> Analysis of <i>ITGA2^{807C/T, 837C/T, 873 G/A}</i> polymorphisms by PCR-RFLP using <i>Bgl II</i> and <i>Asn I</i> endonucleases on 1.5% agarose gel. Lane 7: molecular weight marker; other lanes: different genotypes according to reference 29 (lanes 1, 4, 5: 2/2, lanes 2, 3, 6: 1/2, lane 7: 1/3, lane 8: 2/3, lane 9: 1/1).</p

Cardiovascular Risk Factors in the Study Sample.

<p> <b>Results as mean ± SD; ns: no significant different when p>0.05.</b></p>*<p>THC: tetrahydrocannabinol, † Lp(a): lipoprotein(a), ‡ hsCRP: ultrasensible C-reactive protein.</p><p>(PPAD, premature peripheral arterial diseases; PAOD, peripheral arterial occlusive disease; TAO, thromboangiitis obliterans).</p

Risk Factors for PAOD Patients and TAO.

*<p>p<0.001, †p<0.01, ‡ p<0.05, ns: no significant different when p>0.05.</p><p>(PAOD, peripheral arterial occlusive disease; TAO, thromboangiitis obliterans).</p